We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Candidate Target for Parkinson’s Disease Treatment
News

New Candidate Target for Parkinson’s Disease Treatment

New Candidate Target for Parkinson’s Disease Treatment
News

New Candidate Target for Parkinson’s Disease Treatment

Credit: Lakshmiraman Oza/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Candidate Target for Parkinson’s Disease Treatment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The human brain is lipid rich. Lipids and fatty acids contribute to many important cellular processes. Alpha-synuclein — a protein that plays a critical role in Parkinson’s disease (PD) — is known to interact with and alter the balance of lipids and fatty acids. Investigators from the Brigham and Harvard Medical School are exploring how to rebalance fatty acid metabolism in the brain to find new therapeutic approaches for PD and related conditions. Their previous work has led to the identification of an inhibitor of an enzyme called stearoyl-CoA-desaturase, which is now being tested in human clinical trials. In a new study, they identify LIPE, a lipase that degrades triglycerides to produce fatty acids, as a candidate therapeutic target. Inhibiting LIPE reduced the formation of clusters of α-synuclein inclusions and other characteristics associated with PD in patient-derived neurons. LIPE reduction also alleviated neurodegeneration in a C. elegans model of α-synuclein toxicity.


“Our research led us to become increasingly aware of the role lipid and fatty acid balance may play in Parkinson’s disease,” said co-corresponding author Saranna Fanning, PhD, of the Ann Romney Center for Neurologic Diseases at the Brigham. “Ultimately, we hope this lipid-related target will have promise as a small-molecule therapy for Parkinson’s disease.”


Co-corresponding author Dennis Selkoe, MD, also of the Ann Romney Center for Neurologic Diseases at the Brigham, added, “The identification of LIPE inhibition and a unique co-regulation of fatty acid synthesis and degradation pathways are further evidence that targeting fatty acid metabolism holds promise for Parkinson’s disease.”


Reference: Fanning S, Cirka H, Thies JL, et al. Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy. npj Parkinsons Dis. 2022;8(1):1-17. doi: 10.1038/s41531-022-00335-6


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement